Thiethylperazine

Thiethylperazine

SCHEMBL49124

CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2

The experimentally established mechanism targets of Thiethylperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 5/20 1.00
HTR1A P08908 5/20 1.00
ADRA2A P08913 5/20 1.00
ADRA2C P18825 5/20 1.00
SLC6A2 P23975 5/20 1.00
HTR2A P28223 5/20 1.00
SLC6A4 P31645 5/20 1.00
ADRA1A P35348 5/20 1.00
HRH1 P35367 5/20 1.00
DRD3 P35462 5/20 1.00
SLC6A3 Q01959 5/20 1.00
KCNH2 Q12809 5/20 1.00
CHRM1 P11229 4/20 1.00
DRD1 P21728 4/20 1.00
PDE4D Q08499 4/20 1.00
ADORA3 P0DMS8 3/20 1.00
MC3R P41968 3/20 1.00
CHRM2 P08172 3/20 1.00
OPRM1 P35372 3/20 1.00
HRH3 Q9Y5N1 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiethylperazine SCHEMBL29507072 1.00 HTR1A (1.00) HTR1AADRA2ADRD2ADRA2CSLC6A2
Thiethylperazine SCHEMBL29688372 1.00 HTR1A (1.00) HTR1AADRA2ADRD2ADRA2CSLC6A2
Thiethylperazine SCHEMBL29430925 0.91 HRH1 (0.83) HTR1AADRA2ADRD2ADRA2CSLC6A2
Thiethylperazine SCHEMBL30903918 0.91 HRH1 (0.83) HTR1AADRA2ADRD2ADRA2CSLC6A2
Thiethylperazine SCHEMBL41678 0.91 HRH1 (0.83) HTR1AADRA2ADRD2ADRA2CSLC6A2
Thiethylperazine SCHEMBL17079861 0.91 HRH1 (0.83) HTR1AADRA2ADRD2ADRA2CSLC6A2
Thiethylperazine SCHEMBL10624613 0.91 HRH1 (0.83) HTR1AADRA2ADRD2ADRA2CSLC6A2
Thiethylperazine SCHEMBL41676 0.91 HRH1 (0.83) HTR1AADRA2ADRD2ADRA2CSLC6A2
Thiethylperazine SCHEMBL41677 0.90 ADRA2A (0.80) HTR1AADRA2ADRD2ADRA2CSLC6A2
Thiethylperazine SCHEMBL13724994 0.90 SLC6A2 (0.80) HTR1AADRA2ADRD2ADRA2CSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 6384 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4714452-A1 METHODS FOR TREATING SARS COV-2 INFECTIONS Gilead Sciences, Inc. (US) 2026-03-25 EP claimed
WO-2025082959-A1 A PHENOTHIAZINE-RELATED COMPOUND CONJUGATED TO A PEPTIDE UNIVERSITY OF ULSTER (GB) 2025-04-24 WO claimed
US-20250082647-A1 SPECIFIC DOSAGE OF PHENOTHIAZINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF ALZHEIMER'S DEMENTIA IMMUNGENETICS AG (DE) 2025-03-13 US claimed
US-20240382562-A1 METHODS AND COMPOSITIONS FOR INDUCING DIFFERENTIATION OF HUMAN BROWN ADIPOCYTE PROGENITORS ENERGESIS PHARMACEUTICALS, INC. 2024-11-21 US claimed
US-20240366639-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2024-11-07 US claimed
WO-2024220459-A2 COMBINATION THERAPY WITH LP-PLA2 INHIBITOR AND A SECOND AGENT SCINEURO THERAPEUTICS INC. (US) 2024-10-24 WO claimed
WO-2024191125-A1 METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT 연세대학교 산학협력단 2024-09-19 WO claimed
EP-3863708-B1 MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING BATTELLE MEMORIAL INSTITUTE (US) 2024-09-11 EP claimed
WO-2024083822-A1 IDENTIFYING A SUBJECT SUFFERING FROM ALZHEIMER'S DEMENTIA OR BEING AT RISK OF DEVELOPING ALZHEIMER'S DEMENTIA IMMUNGENETICS AG (DE) 2024-04-25 WO claimed
WO-2023055939-A9 APPARATUS, SYSTEMS AND METHODS FOR TRANSDERMAL DRUG DELIVERY, PERMEABILITY ENHANCEMENT AND AUGMENTATION UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2024-04-25 WO claimed
WO-2001034232-A1 INHALATION NEBULIZER Pari GmbH Spezialisten für effektive Inhalation (DE) 2001-05-17 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
WO-2000045813-A1 METHOD FOR ENHANCEMENT OF DELIVERY OF THC BY THE ADMINISTRATION OF ITS PRODRUGS VIA THE NASAL ROUTE NEW MILLENNIUM PHARMACEUTICAL RESEARCH, INC. (US) 2000-08-10 WO claimed
WO-2000035457-A1 USE OF APOMORPHINE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ORGANIC ERECTILE DYSFUNCTION IN MALES ABBOTT LABORATORIES (US) 2000-06-22 WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
EP-0784474-A2 PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING GF120918A GLAXO WELLCOME INC. (US) 1997-07-23 EP claimed
WO-1996011007-A1 PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING GF120918A GLAXO WELLCOME INC. (US) 1996-04-18 WO claimed
US-5023073-A Method of combating flupropadine poisoning using phenothiazines BURROUGHS WELLCOME CO. (US) 1991-06-11 US claimed
US-4235236-A Device for dispensing drug by combined diffusional and osmotic operations ALZA CORPORATION (US) 1980-11-25 US claimed